Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $23.1667.

Several research analysts have commented on DCTH shares. BTIG Research boosted their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings lowered shares of Delcath Systems from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Zacks Research raised shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. Finally, Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DCTH. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems during the 2nd quarter worth about $26,000. Russell Investments Group Ltd. purchased a new position in Delcath Systems in the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC acquired a new stake in Delcath Systems during the second quarter worth approximately $40,000. Legal & General Group Plc purchased a new stake in shares of Delcath Systems during the 2nd quarter worth approximately $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Delcath Systems during the 2nd quarter worth approximately $151,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

Shares of Delcath Systems stock opened at $17.14 on Monday. Delcath Systems has a one year low of $8.12 and a one year high of $17.42. The company has a market cap of $594.76 million, a PE ratio of 1,715.72 and a beta of 0.52. The business has a 50-day simple moving average of $13.55 and a 200-day simple moving average of $11.35.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. On average, sell-side analysts predict that Delcath Systems will post -0.17 earnings per share for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.